From the reviews: "The target audience ... is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. ... This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a 'one disease' perspective." (Michael Joel Schrift, Doody's Book Reviews, March, 2013)

• Preface.- Clinical instruments to evaluate and guide treatment in schizophrenia.- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders.- Nicotinic mechanisms in psychotic disorders.- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia.- Inhibitors of glycine transport as potential new treatments in schizophrenia.- The role of glutamate in schizophrenia.- Metabotropic glutamate receptors as targets for new treatments in schizophrenia.- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions.- Phosphodiesterase inhibitors as potential new treatments in schizophrenia.- Disease modifying approaches to schizophrenia.- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia.- Transgenic animals reflecting aspects of schizophrenia.- Behavioral animal models of pro-cognitive treatments for schizophrenia.

From the reviews: "The target audience ... is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. ... This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a 'one disease' perspective." (Michael Joel Schrift, Doody's Book Reviews, March, 2013)

• Preface.- Clinical instruments to evaluate and guide treatment in schizophrenia.- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders.- Nicotinic mechanisms in psychotic disorders.- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia.- Inhibitors of glycine transport as potential new treatments in schizophrenia.- The role of glutamate in schizophrenia.- Metabotropic glutamate receptors as targets for new treatments in schizophrenia.- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions.- Phosphodiesterase inhibitors as potential new treatments in schizophrenia.- Disease modifying approaches to schizophrenia.- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia.- Transgenic animals reflecting aspects of schizophrenia.- Behavioral animal models of pro-cognitive treatments for schizophrenia.

From the reviews: "The target audience ... is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. ... This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a 'one disease' perspective." (Michael Joel Schrift, Doody's Book Reviews, March, 2013)

• Preface.- Clinical instruments to evaluate and guide treatment in schizophrenia.- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders.- Nicotinic mechanisms in psychotic disorders.- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia.- Inhibitors of glycine transport as potential new treatments in schizophrenia.- The role of glutamate in schizophrenia.- Metabotropic glutamate receptors as targets for new treatments in schizophrenia.- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions.- Phosphodiesterase inhibitors as potential new treatments in schizophrenia.- Disease modifying approaches to schizophrenia.- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia.- Transgenic animals reflecting aspects of schizophrenia.- Behavioral animal models of pro-cognitive treatments for schizophrenia.